CLOVER BIO-B (02197) surged over 21%, rising 21.15% to HK$2.75 with trading volume of HK$42.2186 million at the time of reporting. On the news front, in June this year, Clover Biopharmaceuticals announced that its respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) (Pre-F trimeric subunit vaccine antigens), developed based on the company's proprietary Trimer-Tag (protein trimerization) vaccine development platform, have completed enrollment of the first batch of subjects and officially launched Phase I clinical trials. Clover Biopharmaceuticals' Chief Executive Officer and Executive Director Liang Guo previously pointed out that while currently approved recombinant protein RSV vaccines are safe and effective, there remain key unmet clinical needs globally—including the inability to prevent and reduce the respiratory disease burden caused by viruses with similar RSV structures such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3).